New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
13:40 EDTJNJ, MDVNJ&J results imply strength for Medivation drug, says William Blair
William Blair believes Johnson & Johnson's (JNJ) Q4 results this morning, which included the trending down of sales for its metastatic prostate cancer drug Zytiga, implies strength for Medivation's (MDVN) Xtandi. The firm believes J&J's decreased sales of Zytiga in Q4 were largely due to competitor Xtandi's U.S. launch in September. William Blair keeps an Outperform rating on shares of Medivation, which are trading up 4% to $57.10 after J&J's results.
News For MDVN;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
07:12 EDTMDVNWilliam Blair names 21 stocks best positioned for volatile markets
Subscribe for More Information
August 27, 2015
19:49 EDTJNJJohnson & Johnson to open shared services headquarters in Florida
Subscribe for More Information
08:35 EDTMDVNMedivation price target raised to $166 at William Blair after talazoparib deal
Subscribe for More Information
August 25, 2015
13:01 EDTJNJJ&J unit to sell Splenda brand to Heartland Food, terms not disclosed
Subscribe for More Information
09:03 EDTJNJAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
06:18 EDTJNJSears names Lynn Pendergrass as Hardlines president
Subscribe for More Information
August 24, 2015
07:02 EDTMDVNMedivation to acquire worldwide rights to Talazoparib from BioMarin
Medivation (MDVN) and BioMarin Pharmaceutical (BMRN) have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib, a highly-potent, orally-available poly ADP ribose polymerase inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer. Under the agreement, Medivation will be responsible for all research, development, regulatory and commercialization activities for all indications on a global basis. Under the terms of the agreement, Medivation will pay BioMarin $410 million upfront, up to an additional $160 million upon the achievement of regulatory and sales-based milestones and mid-single digit royalties for talazoparib. At the closing of the transaction, Medivation will assume all financial obligations associated with the development and commercialization of talazoparib. The closing of the transaction is conditioned on the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is anticipated to close in 2015.
August 21, 2015
09:01 EDTJNJLeerink medical devices analyst holds an analyst/industry conference call
Medical Device Analyst Newitter, along with MEDACorp Specialists Dorance Dillon and Terence Farrell, discuss the Centers for Medicare & Medicaid Services' recently proposed "Comprehensive Care For Joint Replacement Payment Model" and how this model might influence ortho pricing and hospital-vendor relationships on an Analyst/Industry conference call to be held on August 24 at 1 pm.
August 20, 2015
11:33 EDTJNJLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use